Abstract
BackgroundCAR-based cell therapies are hampered by a lack of cell surface target proteins that are also good tumor-specific antigens. HLA-G is an exception as it is only highly expressed in...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
